Rosen Law Firm Alerts BioAge Labs, Inc. Investors to Important Class Action Deadline

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Rosen Law Firm, a prominent global investor rights law firm, has issued a reminder to investors who purchased stock in BioAge Labs, Inc. (NASDAQ: BIOA) that they should take action before the critical deadline of March 10, 2025, for leading plaintiffs in a securities class action lawsuit. This situation arises from the company's initial public offering (IPO) conducted on September 26, 2024.

Important Information for Investors:
If you are an investor in BioAge Labs, Inc., you may have the right to seek compensation. There will be no out-of-pocket fees or costs involved for participating in this class action, as the legal representation operates on a contingency fee basis.

Next Steps:
To participate in the class action lawsuit against BioAge Labs, you can visit this link or contact Phillip Kim, Esq. at 866-767-3653 for further information. A class action has already been initiated, and any investor wishing to serve as the lead plaintiff must file a motion with the court by March 10, 2025. The lead plaintiff will act on behalf of other class members in guiding the case's proceedings.

Why Choose Rosen Law Firm:
The Rosen Law Firm encourages investors to select legal counsel with a proven success record in securities litigation. Many firms sending out notices lack the comparable expertise and are often just intermediaries without the capability to effectively litigate cases themselves. The Rosen Law Firm has a reliable history, having represented global investors and achieved significant settlements, particularly in securities class actions. It was recognized as having the most successful securities class action settlements against a Chinese company at one time and has consistently ranked among the top firms for results since 2013.

Details of the Legal Case:
The lawsuit claims that the defendants misrepresented the safety and progress of their lead product candidate, azelaprag, during the STRIDES Phase 2 clinical trial. Promised topline results were anticipated for 2025, and the company purported to have no safety issues. However, after several participants exhibited elevated liver enzymes signaling potential organ damage, BioAge halted the trial and enrollment. The failure to disclose issues related to liver transaminitis during prior trials renders the IPO-related statements false and misleading, which the lawsuit argues harmed investors once the truth became known.

To get involved in this class action against BioAge Labs, you can go to this link or reach out via phone at 866-767-3653 for more details.

No Class Certified Yet:
It is important to note that no class has been certified at this point, meaning you are not represented unless you choose counsel. You have the option to select your attorney of choice or remain an absent class member. Participation as lead plaintiff is not a requirement to be part of any future recovery.

Stay updated by following us on social media platforms like LinkedIn and Twitter.

Attorney Advertising. Previous outcomes do not guarantee similar results.

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com

BioAge, Lawsuit, Investors